A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
← catalyst calendarNCT07710846 · readout in 509 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
1,500estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-17 | estimated | When the study began enrolling |
| Primary completion | 2028-01-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-10 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Conjunctivitis Allergic
Intervention
- Other: Noninterventional
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with moderate-to-severe allergic conjunctivitis due to cat allergy who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander
measured At visit 1, up to 30 days
Proportion of participants with moderate-to-severe allergic conjunctivitis due to birch tree pollen allergy who report "very bothered" or "extremely bothered" by allergic symptoms
measured At visit 1, up to 30 days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed